<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647487</url>
  </required_header>
  <id_info>
    <org_study_id>17575</org_study_id>
    <secondary_id>J2J-MC-JZLB</secondary_id>
    <secondary_id>2020-002810-42</secondary_id>
    <nct_id>NCT04647487</nct_id>
  </id_info>
  <brief_title>A Study of LY3484356 in Women With Breast Cancer Before Having Surgery</brief_title>
  <acronym>EMBER-2</acronym>
  <official_title>EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose for this study is to see if the study drug, LY3484356, is safe and to determine&#xD;
      what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+),&#xD;
      HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery.&#xD;
      Participation in this study could last up to 2.5 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2021</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in ER Expression</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>ER expression measured by H-score immunohistochemistry (IHC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ki-67 Index</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>Ki-67 index measured by percentage positive scoring by IHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Progesterone Receptor (PR) Expression</measure>
    <time_frame>Baseline, Day 15</time_frame>
    <description>PR expression measured by H-score IHC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Plasma Concentration of LY3484356</measure>
    <time_frame>Baseline through follow-up at Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>LY3484356 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3484356 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3484356</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3484356 Dose Level 1</arm_group_label>
    <arm_group_label>LY3484356 Dose Level 2</arm_group_label>
    <other_name>Imlunestrant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participant Must:&#xD;
&#xD;
          -  Have histologically confirmed invasive ER+, HER2- breast carcinoma&#xD;
&#xD;
          -  Be willing and able to provide pre- and on-treatment tumor samples&#xD;
&#xD;
          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  Be able to swallow capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participant Must Not:&#xD;
&#xD;
          -  Have bilateral invasive breast cancer&#xD;
&#xD;
          -  Have metastatic breast cancer&#xD;
&#xD;
          -  Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer&#xD;
             therapy&#xD;
&#xD;
          -  Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer&#xD;
&#xD;
          -  Have had prior radiotherapy to the ipsilateral chest wall for any malignancy&#xD;
&#xD;
          -  Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor,&#xD;
             or other selective estrogen receptor modulator (SERM), either for osteoporosis or&#xD;
             prevention of breast cancer&#xD;
&#xD;
          -  Have had prior hormone-replacement therapy within 4 weeks of the start of study&#xD;
             treatment&#xD;
&#xD;
          -  Have had major surgery within 28 days prior to randomization to allow for&#xD;
             post-operative healing of the surgical wound and site(s)&#xD;
&#xD;
          -  Be pregnant or breastfeeding&#xD;
&#xD;
          -  Have certain infections such as hepatitis or tuberculosis or HIV that are not well&#xD;
             controlled&#xD;
&#xD;
          -  Have another serious medical condition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-248-7569</phone>
    </contact>
    <investigator>
      <last_name>Reva Basho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Center Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4047781900</phone>
    </contact>
    <investigator>
      <last_name>Manali Ajay Bhave</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hosptial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>312-503-2899</phone>
    </contact>
    <investigator>
      <last_name>Swati Kulkarni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-643-2208</phone>
    </contact>
    <investigator>
      <last_name>Aditya Bardia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-747-0063</phone>
    </contact>
    <investigator>
      <last_name>Rebecca Aft</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Erika P Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>7137988237</phone>
    </contact>
    <investigator>
      <last_name>Stacey Ann Carter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-792-7216</phone>
    </contact>
    <investigator>
      <last_name>Kelly Hunt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>802-847-8400</phone>
    </contact>
    <investigator>
      <last_name>Peter A Kaufman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>003225413189</phone>
    </contact>
    <investigator>
      <last_name>Philippe Aftimos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>003216344634</phone>
    </contact>
    <investigator>
      <last_name>Patrick Neven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <state>Hauts-de-Seine</state>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0033147111515</phone>
    </contact>
    <investigator>
      <last_name>François Clément Bidard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>004991318533553</phone>
    </contact>
    <investigator>
      <last_name>Peter Fasching</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00498951604317</phone>
    </contact>
    <investigator>
      <last_name>Nadia Harbeck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Kliniken Schwerin</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00493855202300</phone>
    </contact>
    <investigator>
      <last_name>Nicole Stahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034932275402</phone>
    </contact>
    <investigator>
      <last_name>María Jesús Vidal Losada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034915868115</phone>
    </contact>
    <investigator>
      <last_name>Miguel Martin Jimenez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0034917567984</phone>
    </contact>
    <investigator>
      <last_name>Eva Ciruelos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <state>Cornwall</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00441872258304</phone>
    </contact>
    <investigator>
      <last_name>Duncan Angus Wheatley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barts Cancer Institute</name>
      <address>
        <city>London</city>
        <state>London City</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00442078823442</phone>
    </contact>
    <investigator>
      <last_name>Peter Schmidt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/3vEdhySNhh4bT91vRoma1P</url>
    <description>A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2)</description>
  </link>
  <verification_date>November 1, 2021</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

